$BSGM
BioSig Technologies, Inc.

2023 Q1 Form 10-K Financial Statement

#000118518523000298 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $5.000K $135.0K $286.0K
YoY Change -37.5% 1587.5% -35.15%
Cost Of Revenue $27.00K $57.00K
YoY Change -71.36%
Gross Profit $108.0K $229.0K
YoY Change 1250.0% -5.37%
Gross Profit Margin 80.0% 80.07%
Selling, General & Admin $6.245M $5.903M $21.38M
YoY Change -2.44% -22.3% -23.24%
% of Gross Profit 5465.74% 9336.24%
Research & Development $1.100M $1.120M $5.800M
YoY Change -31.97% -17.28% 3.53%
% of Gross Profit 1037.04% 2532.75%
Depreciation & Amortization $84.00K $83.00K $293.0K
YoY Change 52.73% 48.21% 47.98%
% of Gross Profit 76.85% 127.95%
Operating Expenses $7.391M $7.106M $27.49M
YoY Change -8.45% -21.11% -18.3%
Operating Profit -$7.386M -$6.998M -$27.27M
YoY Change -8.42% -22.24% -18.4%
Interest Expense $4.000K $2.000K $3.000K
YoY Change 50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.382M -$6.996M -$27.26M
YoY Change -8.47% -22.26% -17.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.332M -$7.045M -$27.05M
YoY Change -9.09% -18.5% -15.24%
Net Earnings / Revenue -146640.0% -5218.52% -9458.74%
Basic Earnings Per Share -$1.19 -$6.33
Diluted Earnings Per Share -$0.12 -$0.14 -$0.64
COMMON SHARES
Basic Shares Outstanding 66.86M shares 48.02M shares 4.307M shares
Diluted Shares Outstanding 6.187M shares 4.307M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.513M $458.0K $458.0K
YoY Change -82.54% -96.07% -96.07%
Cash & Equivalents $1.400M $400.0K
Short-Term Investments $101.0K $101.0K $101.0K
Other Short-Term Assets $275.0K $325.0K $325.0K
YoY Change -11.58% -8.19% -8.19%
Inventory $345.0K $336.0K $336.0K
Prepaid Expenses $275.0K $325.0K
Receivables $17.00K $9.000K $9.000K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.150M $1.128M $1.128M
YoY Change -80.46% -91.88% -91.88%
LONG-TERM ASSETS
Property, Plant & Equipment $630.0K $665.0K $1.370M
YoY Change -46.38% 1.99% 9.08%
Goodwill
YoY Change
Intangibles $1.000K $1.000K
YoY Change 0.0%
Long-Term Investments $94.00K $120.0K $120.0K
YoY Change
Other Assets $244.0K $44.00K $1.184M
YoY Change 480.95% 4.76% 2719.05%
Total Long-Term Assets $3.047M $2.982M $2.982M
YoY Change 97.86% 83.51% 83.51%
TOTAL ASSETS
Total Short-Term Assets $2.150M $1.128M $1.128M
Total Long-Term Assets $3.047M $2.982M $2.982M
Total Assets $5.197M $4.110M $4.110M
YoY Change -58.56% -73.52% -73.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $2.713M $3.165M $3.165M
YoY Change 4.51% 28.55% 28.55%
Deferred Revenue $8.000K $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.814M $3.261M $3.261M
YoY Change 3.88% 26.59% 26.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $368.0K $452.0K $452.0K
YoY Change 15.72% 19.58% 19.58%
Total Long-Term Liabilities $368.0K $452.0K $452.0K
YoY Change 15.72% 19.58% 19.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.814M $3.261M $3.261M
Total Long-Term Liabilities $368.0K $452.0K $452.0K
Total Liabilities $3.182M $3.713M $3.692M
YoY Change 4.57% 25.69% 16.36%
SHAREHOLDERS EQUITY
Retained Earnings -$223.3M -$216.0M
YoY Change 14.32%
Common Stock $67.00K $55.00K
YoY Change 52.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.976M $313.0K $418.0K
YoY Change
Total Liabilities & Shareholders Equity $5.197M $4.110M $4.110M
YoY Change -58.56% -73.52% -73.52%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$7.332M -$7.045M -$27.05M
YoY Change -9.09% -18.5% -15.24%
Depreciation, Depletion And Amortization $84.00K $83.00K $293.0K
YoY Change 52.73% 48.21% 47.98%
Cash From Operating Activities -$5.600M -$4.114M -$21.70M
YoY Change -5.74% -28.21% -17.8%
INVESTING ACTIVITIES
Capital Expenditures $45.00K $58.00K $168.0K
YoY Change -181.82% -140.28% -131.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$45.00K -$58.00K -$168.0K
YoY Change -18.18% -59.72% -69.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.283M
YoY Change -19.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.748M 3.642M $10.57M
YoY Change 124.78% -364300.0% 2.31%
NET CHANGE
Cash From Operating Activities -$5.600M -4.114M -$21.70M
Cash From Investing Activities -$45.00K -58.00K -$168.0K
Cash From Financing Activities $6.748M 3.642M $10.57M
Net Change In Cash $1.103M -530.0K -$11.30M
YoY Change -136.84% -90.98% -31.98%
FREE CASH FLOW
Cash From Operating Activities -$5.600M -$4.114M -$21.70M
Capital Expenditures $45.00K $58.00K $168.0K
Free Cash Flow -$5.645M -$4.172M -$21.87M
YoY Change -4.09% -25.33% -15.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity File Number
EntityFileNumber
001-38659
CY2022 dei Entity Registrant Name
EntityRegistrantName
BIOSIG TECHNOLOGIES, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4333375
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
55 Greens Farms Road, 1st Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Westport
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06880
CY2022 dei City Area Code
CityAreaCode
203
CY2022 dei Local Phone Number
LocalPhoneNumber
409-5444
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
BSGM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
28093855 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66857687 shares
CY2022 dei Auditor Firm
AuditorFirmId
711
CY2022 dei Auditor Name
AuditorName
Friedman LLP
CY2022 dei Auditor Location
AuditorLocation
Marlton, New Jersey
CY2022Q4 us-gaap Cash
Cash
357000 usd
CY2021Q4 us-gaap Cash
Cash
11659000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1881000 usd
CY2022Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
101000 usd
CY2021Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
0 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
325000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
354000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1128000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13894000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
652000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
604000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
120000 usd
CY2021Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
0 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
307000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
326000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43000 usd
CY2022Q4 us-gaap Assets
Assets
4110000 usd
CY2021Q4 us-gaap Assets
Assets
15519000 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
120000 usd
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
86000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2179000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
32000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
91000 usd
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
82000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
283000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3261000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2576000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
373000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
452000 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
378000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3713000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2954000 usd
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
105 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
105 shares
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2021Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
105000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54610638 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35567180 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35567180 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
55000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
216232000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
201127000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215974000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188922000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
313000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
12241000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
219000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12460000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4110000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15519000 usd
CY2022 us-gaap Revenues
Revenues
286000 usd
CY2021 us-gaap Revenues
Revenues
441000 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
57000 usd
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
199000 usd
CY2022 us-gaap Gross Profit
GrossProfit
229000 usd
CY2021 us-gaap Gross Profit
GrossProfit
242000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5821000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5602000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21380000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27853000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
293000 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
198000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
27494000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
33653000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-27265000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-33411000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
553000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27262000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32856000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
373000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
441000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4412000 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-27262000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-32856000 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-210000 usd
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-939000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-27052000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-31917000 usd
CY2022 us-gaap Dividends Preferred Stock
DividendsPreferredStock
9000 usd
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
9000 usd
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
210000 usd
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27271000 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31926000 usd
CY2022 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.64
CY2021 bsgm Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.95
CY2022 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
42632595 shares
CY2021 bsgm Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
33511941 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
25172000 usd
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3975000 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000 usd
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
995000 usd
CY2021 us-gaap Stockholders Equity Other
StockholdersEquityOther
9004000 usd
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
321000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5525000 usd
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
9000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-32856000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12460000 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2109000 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
528000 usd
CY2022 us-gaap Stockholders Equity Other
StockholdersEquityOther
8283000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.25
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
218000 usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
15000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2303000 usd
CY2022 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
210000 usd
CY2022 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
-210000 usd
CY2022 us-gaap Dividends Preferred Stock
DividendsPreferredStock
9000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-27262000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-27262000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-32856000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
293000 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
198000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
553000 usd
CY2022 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
-15000 usd
CY2021 us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
-321000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9000 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2022 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
220000 usd
CY2021 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
0 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-284000 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1114000 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-30000 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
50000 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-32000 usd
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
38000 usd
CY2021 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
60000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
776000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1988000 usd
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-365000 usd
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-396000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21705000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26399000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
168000 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
542000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-542000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8283000 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9004000 usd
CY2022 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
2070000 usd
CY2021 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1300000 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
218000 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10571000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10332000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11302000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16609000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11659000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28268000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11659000 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
105000 usd
CY2021 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
9000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
9000 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
502000 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
800000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400000 usd
CY2022Q4 bsgm Working Capital Deficit
WorkingCapitalDeficit
2100000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21700000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets,  stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
2 pure
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30Y
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37000 usd
CY2022 us-gaap Contract With Customer Asset Purchase
ContractWithCustomerAssetPurchase
254000 usd
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-286000 usd
CY2022Q4 us-gaap Policyholder Funds
PolicyholderFunds
5000 usd
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2021 us-gaap Contract With Customer Asset Purchase
ContractWithCustomerAssetPurchase
478000 usd
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-441000 usd
CY2021Q4 us-gaap Policyholder Funds
PolicyholderFunds
37000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
32000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
5000 usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
37000 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2022 and 2021, deposits in excess of FDIC limits were $0.05 million and $11.2 million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
50000.00 usd
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
11200000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1477000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1881000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
336000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1881000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1141000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
329000 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
43000 usd
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
42000 usd
CY2022Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2021Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
1000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
44000 usd
CY2021Q4 us-gaap Other Assets
OtherAssets
43000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5800000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5600000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
665000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
652000 usd
CY2022 us-gaap Depreciation
Depreciation
273915 usd
CY2021 us-gaap Depreciation
Depreciation
179136 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9667798 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5612112 shares
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
19006 usd
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
19006 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1266000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
981000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
601000 usd
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
6590 sqft
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
14232 usd
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
36756 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
37625 usd
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
868 usd
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
1400 sqft
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2023Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
7155 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41227 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-41930 usd
CY2023Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
703 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
15130 usd
CY2022Q2 us-gaap Security Deposit
SecurityDeposit
27404 usd
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
502445 usd
CY2022 bsgm Number Of Leases
NumberOfLeases
2 pure
CY2022Q4 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2021Q4 bsgm Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
803000 usd
CY2022Q4 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
290000 usd
CY2021Q4 bsgm Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
199000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
705000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
604000 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
438129 usd
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
479746 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
765000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
656000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
283000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
452000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
373000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
357000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
370000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
106000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
833000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
68000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
765000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
373000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
441000 usd
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
37000 usd
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
28000 usd
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2022 us-gaap Lease Cost
LeaseCost
438000 usd
CY2021 us-gaap Lease Cost
LeaseCost
480000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4333 usd
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q3 bsgm Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2022Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2021Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
0 usd
CY2022 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
254000 usd
CY2022 bsgm Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-39000 usd
CY2022 us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
2000 usd
CY2022Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
104000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
104000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
13000 usd
CY2022Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
225000 usd
CY2022Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
4000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
646000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000 usd
CY2022Q4 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
33000 usd
CY2021Q4 bsgm Accrued Reimbursements Current
AccruedReimbursementsCurrent
56000 usd
CY2022Q4 bsgm Accrued Consulting Current
AccruedConsultingCurrent
546000 usd
CY2021Q4 bsgm Accrued Consulting Current
AccruedConsultingCurrent
264000 usd
CY2022Q4 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
625000 usd
CY2021Q4 bsgm Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
367000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
256000 usd
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
38000 usd
CY2022Q4 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
220000 usd
CY2021Q4 bsgm Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
84000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
513000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
552000 usd
CY2022Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
13000 usd
CY2021Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
613000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2852000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2179000 usd
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.75
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.27
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.25
CY2022 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
209682 usd
CY2020Q3 us-gaap Preferred Stock Dividend Payment Terms
PreferredStockDividendPaymentTerms
declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter.
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
50
CY2020Q3 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors.
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54610638 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35567180 shares
CY2021Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
658868 shares
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2658224 usd
CY2020Q3 bsgm At The Market Offering
AtTheMarketOffering
45000000 usd
bsgm Commission Rate
CommissionRate
0.03 pure
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
251720 shares
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1300135 usd
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
40365 usd
CY2022 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
259165 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.4
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.25
CY2022 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
873000 shares
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
218250 usd
CY2022Q2 bsgm At The Market Offering
AtTheMarketOffering
10000000 usd
CY2022Q2 bsgm Commission Rate
CommissionRate
0.025 pure
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3084791 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2069582 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
121926 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5265945 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5265945 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4555484 shares
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3149069 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3568497 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.59
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
110961
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1818000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.69
CY2021 bsgm Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P10Y
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9375 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.96
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
808638 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4568484 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.57
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1428000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.12
CY2022 bsgm Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P10Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1441000 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.54
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4555484 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.49
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
3000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3149069 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.83
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000 usd
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
2.44
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.97
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
immediate to three years from the date of issuance
CY2022 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
1.72
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
immediate to three years from the date of issuance
CY2021Q2 bsgm Options Modified
OptionsModified
145000 shares
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
182514 usd
CY2021Q2 bsgm Options Modified
OptionsModified
221240 shares
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
111402 usd
CY2022Q1 bsgm Options Modified
OptionsModified
100000 shares
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
15181 usd
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4217111 shares
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
90865 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9626 pure
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0382 pure
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1446200 shares
CY2020Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
5.44
CY2020 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M18D
CY2020Q4 bsgm Class Of Warrant Or Rights Outstanding Intrinsic Value
ClassOfWarrantOrRightsOutstandingIntrinsicValue
1500 usd
CY2021 bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
125000 shares
CY2021 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
4.8
CY2021 bsgm Warrants Granted Weighted Average Remaining Contractual Term
WarrantsGrantedWeightedAverageRemainingContractualTerm
P5Y
CY2021 bsgm Class Of Warrant Or Rights Cancelled
ClassOfWarrantOrRightsCancelled
752290 shares
CY2021 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Cancelled
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsCancelled
5
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
818910 shares
CY2021Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
5.74
CY2021 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P5Y3M18D
CY2022 bsgm Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
4271201 shares
CY2022 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.05
CY2022 bsgm Warrants Granted Weighted Average Remaining Contractual Term
WarrantsGrantedWeightedAverageRemainingContractualTerm
P4Y
CY2022 bsgm Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
873000 shares
CY2022 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised
0.25
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4217111 shares
CY2022Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
1.89
CY2022 bsgm Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P4Y3M18D
CY2022Q4 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding
4217111 shares
CY2022Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Vested And Expected To Vest Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding
1.89
CY2022 bsgm Warrants Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P4Y3M18D
CY2022Q4 bsgm Class Of Warrant Or Rights Vested And Expected To Vest Outstanding Intrinsic Value
ClassOfWarrantOrRightsVestedAndExpectedToVestOutstandingIntrinsicValue
3960 usd
CY2022Q4 bsgm Class Of Warrant Or Rights Exercisable
ClassOfWarrantOrRightsExercisable
3026123 shares
CY2022Q4 bsgm Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
2.46
CY2022 bsgm Warrants Exercisable Weighted Average Remaining Contractual Term
WarrantsExercisableWeightedAverageRemainingContractualTerm
P3Y10M24D
CY2022Q4 bsgm Class Of Warrant Or Rights Exercisable Intrinsic Value
ClassOfWarrantOrRightsExercisableIntrinsicValue
3350 usd
CY2022Q4 us-gaap Share Price
SharePrice
0.42
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
90865 usd
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
219000 usd
CY2022 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Issuance Of Equity By Subsidiary To Noncontrolling Interests
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesIssuanceOfEquityBySubsidiaryToNoncontrollingInterests
292000 usd
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
30000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
109725 usd
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
50000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
232375 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
375000 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2650071 shares
CY2021Q3 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
206250 shares
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
550000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1078679 shares
CY2020Q4 us-gaap Minority Interest
MinorityInterest
802000 usd
CY2021 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
348000 usd
CY2021 bsgm Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Due Change In Fair Value Of Modified Option
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesDueChangeInFairValueOfModifiedOption
8000 usd
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-939000 usd
CY2022 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
322000 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-210000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-21000 usd
CY2022Q1 bsgm Monthly Service Fee
MonthlyServiceFee
40000 usd
CY2022Q1 bsgm Commission Rate
CommissionRate
0.10 pure
CY2022Q4 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
80 usd
CY2021Q4 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
0 usd
CY2017Q1 bsgm Agreement Term
AgreementTerm
P10Y
CY2019Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
625000 usd
CY2019Q4 us-gaap Other Commitment
OtherCommitment
100000 usd
CY2021 us-gaap Payments For Royalties
PaymentsForRoyalties
75000 usd
CY2019Q4 bsgm Royalty Percentage Of Net Sales
RoyaltyPercentageOfNetSales
0.10 pure
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
247622 usd
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
252452 usd
CY2022 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1882530 usd
CY2022 us-gaap Revenues
Revenues
286000 usd
CY2021 us-gaap Revenues
Revenues
441000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
27494000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
33653000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-27265000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-33411000 usd
CY2022Q4 us-gaap Assets
Assets
4110000 usd
CY2021Q4 us-gaap Assets
Assets
15519000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
120000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
86208 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
133000000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5645000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31170000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36815000 usd
CY2022 bsgm Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
-0.21 pure
CY2022 bsgm Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
-0.21 pure
CY2021 bsgm Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate1
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate1
-0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.003 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.013 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.207 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.197 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0 pure
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27948000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24308000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7814000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6862000 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1053000 usd
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36815000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31170000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
usd
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001530766

Files In Submission

Name View Source Status
bsgm-20221231_cal.xml Edgar Link unprocessable
0001185185-23-000298-index-headers.html Edgar Link pending
0001185185-23-000298-index.html Edgar Link pending
0001185185-23-000298.txt Edgar Link pending
0001185185-23-000298-xbrl.zip Edgar Link pending
biosig20221231_10k.htm Edgar Link pending
bsgm-20221231.xsd Edgar Link pending
ex_492406.htm Edgar Link pending
ex_492407.htm Edgar Link pending
ex_492408.htm Edgar Link pending
ex_492409.htm Edgar Link pending
ex_492410.htm Edgar Link pending
ex_493556.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
bsgm-20221231_def.xml Edgar Link unprocessable
bsgm-20221231_lab.xml Edgar Link unprocessable
bsgm-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
biosig20221231_10k_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending